A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.

Journal: Respiratory medicine

PMID: 28137501

Abstract

BACKGROUND: The contribution of fluticasone furoate (FF) on lung function in the FF/vilanterol (VI) 100/25 μg combination has been demonstrated numerically, but not statistically.

Authors

Thomas M Siler

Midwest Chest Consultants, PC, St Charles, MO, USA. Electronic address: Thomas.siler.md@midwestchest.com.
Atsushi Nagai

Research Institute for Respiratory Disease, Shin-Yurigaoka General Hospital, Kawasaki, Kanagawa, Japan.
Catherine A Scott-Wilson

GlaxoSmithKline, Research Triangle Park, NC, USA.
Dawn A Midwinter

GlaxoSmithKline, Stockley Park, Uxbridge, UK.
Courtney Crim

GlaxoSmithKline, Research Triangle Park, NC, USA.

Keywords

Administration, Inhalation Adrenergic beta-2 Receptor Agonists Adult Aged Androstadienes Benzyl Alcohols Chlorobenzenes Double-Blind Method Drug Administration Schedule Drug Combinations Female Forced Expiratory Volume Glucocorticoids Humans Kaplan-Meier Estimate Male Middle Aged Pulmonary Disease, Chronic Obstructive Quality of Life

External Resources

View on PubMed Access via DOI PubMed (28137501)

A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals